Pacira BioSciences, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On November 17, 2026, Pacira BioSciences was acquired by Viatris Inc. for $36.50 per share in cash via tender offer and merger. As a result, Pacira's $36.50 Merger Consideration triggered a Common Stock Change Event and Make-Whole Fundamental Change under the indenture for Pacira's 2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9). The company executed a First Supplemental Indenture converting noteholders' stock conversion rights into cash-settlement rights: $1,103.89 per $1,000 principal (Nov 17–Jan 8, 2027, with make-whole adjustment of 4.9684 additional shares), or $922.54 per $1,000 principal thereafter (base conversion rate 25.2752 shares × $36.50). No repurchase offer triggered under Section 14.05.
Why this rating
Merger itself is transformational (business ceases as independent entity), but filing concerns only debt conversion mechanics—routine post-M&A indenture amendment. No dollar quantification of note principal outstanding in filing. Event is boilerplate for convertible noteholders in an M&A transaction; no new material operational or financial disclosure.
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.